期刊文献+

缩泉胶囊配合酒石酸托特罗定治疗膀胱过度活动症肾虚型36例疗效观察 被引量:3

Observation of Suoquan capsule combined with Tolterodine tartrate on overactive bladder
下载PDF
导出
摘要 目的观察缩泉胶囊配合酒石酸托特罗定治疗膀胱过度活动症肾虚型临床疗效。方法将68例膀胱过度活动症肾虚型患者随机分为2组,对照组32例予酒石酸托特罗定治疗,治疗组36例在对照组治疗基础上加用缩泉胶囊治疗。2组均6周为1个疗程,1个疗程后观察治疗前后24 h平均排尿次数、平均24 h尿失禁次数、每次排尿量和不良反应例数。结果治疗组治疗后24 h平均排尿次数少于对照组(P<0.05),每次排尿量多于对照组(P<0.05)。2组治疗后平均24 h尿失禁次数比较差异无统计学意义(P>0.05)。治疗组不良反应率低于对照组(P<0.05)。结论缩泉胶囊配合酒石酸托特罗定治疗膀胱过度活动症肾虚型疗效确切。 Objective To observe the therapeutic effect of Suoquan capsule combined with Tolterodine tartrate on overactive bladder.Methods 68 cases of overactive bladder were randomly divided into treatment group(n=36),which were treated by Suoquan capsule combined with Tolterodine tartrate and control group(n=32),which were given Tolterodine tartrate.The course was six weeks in two groups.The average frequency of urination before and after treatment for 24 h,the average 24-h urinary incontinence,each voided volume and adverse reaction cases were recorded after a course.Results The average frequency of urination after treatment for 24 h was decreased as compared with that before treatment in treatment group,and each voided volume was increased(P0.05).There was no significant difference between two groups on the average 24-h urinary incontinence after treatment.Adverse reaction cases in treatment group was lower than that in control group(P0.05).Conclusion Suoquan capsule combined with Tolterodine tartrate has positive effect on overactive bladder.
出处 《河北中医》 2012年第3期420-422,共3页 Hebei Journal of Traditional Chinese Medicine
关键词 膀胱疾病 肾虚 中西医结合疗法 Bladder disease Nephrasthenia Combined therapy of Chinese and Western medicine
  • 相关文献

参考文献5

二级参考文献11

共引文献171

同被引文献38

  • 1梁玉梅,黄安兰,徐湘玉.缩泉胶囊调治夜尿频数70例临床观察[J].中国医药指南,2008,6(15):99-100. 被引量:10
  • 2蔡剑,曾文彤,张培海,李广森,夏雨果,吴天浪,彭成.缩泉丸与琥珀酸索利那新联合治疗肾虚型膀胱过度活动症72例临床观察[J].中药与临床,2013,4(5):39-41. 被引量:12
  • 3那彦群,叶章群,孙光.中国泌尿外科疾病诊断治疗指南:2011版[M].北京:人民卫生出版社,2011:117-123.
  • 4Abrams P,Cardozo L,Fall M,et al.The standardisation of terminology of lower urinary tract function:report from the Standardisation Sub-committee of the International Continence Society[J].Neurourol Urodyn,2002,21 (2):167-178.
  • 5Wein AJ,Rackley RR.Overactive bladder:a better understanding of pathophysiology,diagnosis and management[J].J Urol,2006,175(3 Pt 2):S5-10.
  • 6Oh SJ,Ku JH,Choo MS,et al.Health-related quality of life and sexual function in women with stress urinary incontinence and overactive bladder[J].Int J Urol,2008,15(1):62-67.
  • 7Homma Y,Yoshida M,Seki N,et al.Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score[J].Urology,2006,68(2):318-323.
  • 8Barbier P,Renzetti AR,Turbanti L,et al.Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine[J].Eur J Pharmcol,1995,290(2):125-132.
  • 9Hoti E,Censi R,Ricciutelli M,et al.Validation of an HPLC-MS method for rociverine tablet dissolution analysis[J].J Pharm Biomed Anal,2008,47 (2):422-428.
  • 10王永炎;严世芸.实用中医内科学[M]上海:上海科学技术出版社,1985307.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部